HUE057499T2 - Antitest - Google Patents
AntitestInfo
- Publication number
- HUE057499T2 HUE057499T2 HUE16835194A HUE16835194A HUE057499T2 HU E057499 T2 HUE057499 T2 HU E057499T2 HU E16835194 A HUE16835194 A HU E16835194A HU E16835194 A HUE16835194 A HU E16835194A HU E057499 T2 HUE057499 T2 HU E057499T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015158414 | 2015-08-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE057499T2 true HUE057499T2 (hu) | 2022-06-28 |
Family
ID=57984391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16835194A HUE057499T2 (hu) | 2015-08-10 | 2016-08-09 | Antitest |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20180230212A1 (hu) |
| EP (2) | EP4005594A1 (hu) |
| JP (1) | JP6534074B2 (hu) |
| CN (2) | CN108138172B (hu) |
| CA (1) | CA2995166C (hu) |
| CY (1) | CY1124949T1 (hu) |
| DK (1) | DK3336185T3 (hu) |
| ES (1) | ES2905534T3 (hu) |
| HR (1) | HRP20220069T1 (hu) |
| HU (1) | HUE057499T2 (hu) |
| LT (1) | LT3336185T (hu) |
| PL (1) | PL3336185T3 (hu) |
| PT (1) | PT3336185T (hu) |
| SI (1) | SI3336185T1 (hu) |
| WO (1) | WO2017026497A1 (hu) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4005594A1 (en) * | 2015-08-10 | 2022-06-01 | Osaka University | Antibody against cd98hc |
| CN114773471A (zh) | 2016-10-20 | 2022-07-22 | 天境生物科技(上海)有限公司 | 新的cd47单克隆抗体及其应用 |
| EP3600352A1 (en) * | 2017-03-20 | 2020-02-05 | City of Hope | Cs1 targeted chimeric antigen receptor-modified t cells for treatment of al amyloidosis |
| CA3090519A1 (en) | 2018-02-07 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| CN112105386A (zh) * | 2018-10-31 | 2020-12-18 | 天境生物科技(上海)有限公司 | 新的cd47抗体及其使用方法 |
| CN112194722A (zh) * | 2020-09-10 | 2021-01-08 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 抗h5亚型禽流感病毒的重组抗体及其制备方法和应用 |
| TW202322822A (zh) | 2021-08-20 | 2023-06-16 | 日商大塚製藥股份有限公司 | 組合醫藥 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002326318A1 (en) * | 2001-06-26 | 2003-03-03 | Trustees Of Tufts College | Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer |
| TWI390034B (zh) * | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
| JPWO2007142309A1 (ja) * | 2006-06-09 | 2009-10-29 | 道男 石橋 | 腎糸球体治療剤のスクリーニング方法 |
| GB0615662D0 (en) * | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| CN103038255A (zh) * | 2010-03-26 | 2013-04-10 | 国立大学法人德岛大学 | 新抗cd98抗体及其用途 |
| JP5906447B2 (ja) * | 2011-01-13 | 2016-04-20 | 国立研究開発法人産業技術総合研究所 | 上皮性卵巣癌鑑別マーカー |
| CA2856873A1 (en) * | 2011-11-23 | 2013-05-30 | Igenica, Inc. | Anti-cd98 antibodies and methods of use thereof |
| EP4005594A1 (en) * | 2015-08-10 | 2022-06-01 | Osaka University | Antibody against cd98hc |
-
2016
- 2016-08-09 EP EP21203138.9A patent/EP4005594A1/en active Pending
- 2016-08-09 HR HRP20220069TT patent/HRP20220069T1/hr unknown
- 2016-08-09 DK DK16835194.8T patent/DK3336185T3/da active
- 2016-08-09 WO PCT/JP2016/073503 patent/WO2017026497A1/ja active Application Filing
- 2016-08-09 JP JP2017534477A patent/JP6534074B2/ja active Active
- 2016-08-09 HU HUE16835194A patent/HUE057499T2/hu unknown
- 2016-08-09 US US15/751,717 patent/US20180230212A1/en not_active Abandoned
- 2016-08-09 CN CN201680058931.4A patent/CN108138172B/zh active Active
- 2016-08-09 LT LTEPPCT/JP2016/073503T patent/LT3336185T/lt unknown
- 2016-08-09 CA CA2995166A patent/CA2995166C/en active Active
- 2016-08-09 PL PL16835194T patent/PL3336185T3/pl unknown
- 2016-08-09 EP EP16835194.8A patent/EP3336185B1/en active Active
- 2016-08-09 CN CN202110880210.4A patent/CN113683696A/zh active Pending
- 2016-08-09 ES ES16835194T patent/ES2905534T3/es active Active
- 2016-08-09 SI SI201631436T patent/SI3336185T1/sl unknown
- 2016-08-09 PT PT168351948T patent/PT3336185T/pt unknown
-
2021
- 2021-11-16 US US17/527,681 patent/US20220064287A1/en not_active Abandoned
-
2022
- 2022-02-02 CY CY20221100090T patent/CY1124949T1/el unknown
-
2023
- 2023-07-21 US US18/356,489 patent/US20230357390A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2905534T3 (es) | 2022-04-11 |
| US20220064287A1 (en) | 2022-03-03 |
| DK3336185T3 (en) | 2022-01-24 |
| PT3336185T (pt) | 2022-01-27 |
| EP3336185A1 (en) | 2018-06-20 |
| CY1124949T1 (el) | 2023-01-05 |
| PL3336185T3 (pl) | 2022-02-28 |
| US20230357390A1 (en) | 2023-11-09 |
| EP4005594A1 (en) | 2022-06-01 |
| SI3336185T1 (sl) | 2022-04-29 |
| CN108138172A (zh) | 2018-06-08 |
| CA2995166C (en) | 2023-10-31 |
| CN113683696A (zh) | 2021-11-23 |
| HRP20220069T1 (hr) | 2022-04-15 |
| CA2995166A1 (en) | 2017-02-16 |
| US20180230212A1 (en) | 2018-08-16 |
| LT3336185T (lt) | 2022-02-10 |
| CN108138172B (zh) | 2021-07-27 |
| EP3336185B1 (en) | 2021-12-22 |
| JPWO2017026497A1 (ja) | 2018-06-21 |
| WO2017026497A1 (ja) | 2017-02-16 |
| JP6534074B2 (ja) | 2019-06-26 |
| EP3336185A4 (en) | 2019-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1253507A1 (zh) | 抗 ror1 抗體 | |
| HK1256116A1 (zh) | 抗lag-3抗體 | |
| HK1254836A1 (zh) | 抗-ror1抗體 | |
| HK1254310A1 (zh) | 抗garp抗體 | |
| IL253633A0 (en) | Anti-transthyretin antibodies | |
| GB201521393D0 (en) | Antibodies | |
| GB201521391D0 (en) | Antibodies | |
| HK1246804A1 (zh) | Tau結合抗體 | |
| GB201521382D0 (en) | Antibodies | |
| IL256099A (en) | antibody | |
| HK1255056A1 (zh) | 抗cd115抗體 | |
| HUE059592T2 (hu) | Anti-transztiretin antitestek | |
| IL268889A (en) | Anti-EPHA4 antibody | |
| GB201515351D0 (en) | Antibody | |
| PT3336185T (pt) | Anticorpo | |
| HK1249549A1 (zh) | 抗體 | |
| GB201600871D0 (en) | Antibody | |
| GB201509907D0 (en) | Antibodies | |
| GB201522394D0 (en) | Antibodies | |
| GB201503438D0 (en) | Antibodies | |
| GB201513447D0 (en) | Antibody | |
| GB201518728D0 (en) | Antibodies | |
| GB201515572D0 (en) | Anti-LAG-3 antibodies | |
| GB201515570D0 (en) | Anti-LAG-3 antibodies | |
| GB201508437D0 (en) | Antibodies |